<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529800</url>
  </required_header>
  <id_info>
    <org_study_id>HM-VICT-102</org_study_id>
    <nct_id>NCT02529800</nct_id>
  </id_info>
  <brief_title>Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetics Incorporating a Comparison of Fed/Fasted Pharmacokinetics of HIP1402 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the PK charateristics and the effect of food on the PK in healthy male
      volunteers who receive HIP1402 capsule in fed versus fasted condition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, three-way crossover clinical trial to investigate the
      pharmacokinetics incorporating a comparison of fed/fasted pharmacokinetics of HIP1402 in
      healthy male volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tamsulosin, AUC(AUClast, AUCinf),</measure>
    <time_frame>pre-dose(0 h), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tamsulosin, Cmax</measure>
    <time_frame>pre-dose(0 h), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tamsulosin, Tmax</measure>
    <time_frame>pre-dose(0 h), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tamsulosin, t1/2</measure>
    <time_frame>pre-dose(0 h), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tamsulosin, CL/F</measure>
    <time_frame>pre-dose(0 h), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tamsulosin, Vz/F</measure>
    <time_frame>pre-dose(0 h), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High fat diet+HGP0412 → High fat diet+HIP1402 → fasted state+HIP1402</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High fat diet+HIP1402 → fasted state+HIP1402 → High fat diet+HGP0412</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fasted state+HIP1402 → High fat diet+HGP0412 → High fat diet+HIP1402</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIP1402</intervention_name>
    <description>Tamsulosin HCl 0.4mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0412</intervention_name>
    <description>Tamsulosin HCl 0.2mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteer, age 19~50 years

          2. Weight ≥55kg and ≤90kg, The result of Body Mass Index(BMI) is not less than 18 kg/m2 ,
             no more than 27 kg/m2

          3. Subject who has the ability to comprehend the study objectives, contents and the
             property of the study drug before participating in the trial

          4. Subject who has the ability and willingness to participate the whole period of trial

        Exclusion Criteria:

          1. Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in kidney, liver, cardiovascular system, respiratory system,
             endocrine system, or neuropsychiatric system.

          2. History of relevant drug allergies or clinically significant hypersensitivity
             reaction.

          3. Systolic Blood Pressure: lower than 100mmHg or higher than 150mmHg, Diastolic Blood
             Pressure: lower than 60mmHg or higher than 100mmHg

          4. Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a
             half times.

          5. Subjects who took prescription drugs within 14 days from the patient screening or
             non-prescription medicine within 7 days which can affect the result of this clinical
             trial (acceptable according to the investigator's judgement)

          6. Intake of more than 210g of alcohol per week or who can't abstain from alcohol during
             the trial.

          7. Subjects who smoke more than 10 cigarettes per day or who can't quit smoking during
             the trial.

          8. Positive screening on Hepatitis B surface antigen(HBsAg), anti-Hepatitis C virus(HCV)
             or anti-Human immunodeficiency virus(HIV).

          9. Subjects who judged ineligible by the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

